Compare Baxter International Inc (BAX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Neurocrine Biosciences Inc — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.27B), while Neurocrine Biosciences Inc trades at $152.18 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Baxter International Inc pays a 0.14% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BAX | NBIX | |
|---|---|---|
Market Cap | $14.27B | $16.46B |
Sector | Health | Health |
52-Week High | $28.35 | $185.50 |
52-Week Low | $15.80 | $123.10 |
Enterprise Value | $21.79B | $16.48B |
Dividend Yield | 0.14% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
